Table 2.
Two-Way Sensitivity Analysis: IMRT Cost-Effectiveness (ICER) Varying QoL and Efficacy for SBRT
| QoL (%) | Change (%) | Efficacy at 5 Years (bPFS) |
|||||
|---|---|---|---|---|---|---|---|
| −6% | −4% | −2% | Base | 2% | 4% | ||
| 0.84 | 0.86 | 0.88 | 0.90 | 0.92 | 0.94 | ||
| 0.765 | −5.0 | 8,232 | 8,987 | 10,254 | 11,678 | 13,286 | 15,115 |
| 0.864 | −4.0 | 20,238 | 27,919 | 36,841 | 49,979 | 76,013 | 134,220 |
| 0.873 | −3.0 | 23,238 | 30,380 | 40,921 | 58,390 | 92,879 | 192,587 |
| 0.891 | −1.0 | 40,110 | 50,361 | 81,585 | 175,170 | * | * |
| 0.9 | Base | 52,918 | 75,037 | 162,151 | * | * | * |
| 0.909 | 1.0 | 77,742 | 164,700 | * | * | * | * |
| 0.927 | 3.0 | 222,674 | * | * | * | * | * |
| 0.945 | 5.0 | * | * | * | * | * | * |
NOTE. ICER per QALYs gained for IMRT when relaxing the assumptions for SBRT efficacy and utility. All ICERs are expressed in $/QALYs.
Abbreviations: bPFS, biologic progression-free survival; ICER, incremental cost-effectiveness ratio; IMRT, intensity-modulated radiation therapy; QoL, quality of life; SBRT, stereotactic body radiation therapy.
*
Dominated.